On September 26, 2025, Hualan Co., Ltd. (301093.SZ) disclosed its intention to allocate 50 million yuan from its own reserves to set up a fully-owned subsidiary in Hainan Province. This subsidiary will be dedicated to pioneering AI-driven innovative drug research and development (R&D) solutions and services. The strategic initiative is designed to foster fresh avenues for business expansion, amplify the company's market presence, and facilitate robust growth. In tandem, Hualan Co., Ltd. will undertake comprehensive planning for the subsidiary, harnessing synergistic effects to diversify its business portfolio and extend its market penetration.